Drug intelligence / Profile preview

coronavirus vaccine-Beijing 302 Hospital-COVID-19

Development stage: Unknown
Lead developer: The Fifth Medical Center of the PLA General Hospital
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

coronavirus vaccine-Beijing 302 Hospital-COVID-19 refers to a SARS-CoV-2 vaccine evaluated in clinical trials sponsored by the Beijing 302 Hospital (also known as the Fifth Medical Center of the PLA General Hospital). This designation is typically used in clinical trial registries and pipeline databases to identify the inactivated SARS-CoV-2 vaccine (Vero Cell) used in Phase 4 studies, such as NCT04895709, which investigated the safety and immunogenicity of COVID-19 vaccination in patients with HIV infection. The vaccine consists of chemically inactivated SARS-CoV-2 viral particles that retain their structural integrity, allowing the immune system to recognize multiple antigens including the spike, nucleocapsid, envelope, and membrane proteins. Administered via intramuscular injection, the vaccine stimulates the production of neutralizing antibodies and T-cell responses to provide protection against COVID-19.

Other names: COVID-19 vaccine (Beijing 302 Hospital)SARS-CoV-2 vaccine (Beijing 302 Hospital)Coronavirus vaccine (Beijing 302 Hospital)

Targets

SARS-CoV-2 spikeN (Nucleocapsid protein)E (Tick-borne encephalitis virus envelope protein)M protein (SARS-CoV-2 membrane protein)

Beyond the preview

Go deeper on coronavirus vaccine-Beijing 302 Hospital-COVID-19.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on coronavirus vaccine-Beijing 302 Hospital-COVID-19.

Explore the full profile